ZANAMIVIR

Zanamivir Adverse Events Reported to the FDA Over Time

How are Zanamivir adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Zanamivir, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Zanamivir is flagged as the suspect drug causing the adverse event.

Most Common Zanamivir Adverse Events Reported to the FDA

What are the most common Zanamivir adverse events reported to the FDA?

Death	26 (4.48%)
Acute Respiratory Distress Syndrome	20 (3.44%)
Cytolytic Hepatitis	17 (2.93%)
Multi-organ Failure	17 (2.93%)
Respiratory Failure	17 (2.93%)
Drug Exposure During Pregnancy	16 (2.75%)
Renal Failure	16 (2.75%)
Pancytopenia	13 (2.24%)
Haemodynamic Instability	12 (2.07%)
Cardiac Arrest	10 (1.72%)
Hypoxia	10 (1.72%)
	Show More
Thrombocytopenia	10 (1.72%)
Blood Creatinine Increased	9 (1.55%)
Bradycardia	9 (1.55%)
Encephalopathy	9 (1.55%)
Haemoglobin Decreased	9 (1.55%)
Pathogen Resistance	9 (1.55%)
Drug Ineffective	8 (1.38%)
Pyrexia	7 (1.2%)
Abortion Spontaneous	6 (1.03%)
Accidental Overdose	6 (1.03%)
Hepatocellular Injury	6 (1.03%)
Hypotension	6 (1.03%)
Ileus Paralytic	6 (1.03%)
Renal Impairment	6 (1.03%)
Alanine Aminotransferase Increased	5 (.86%)
Aspartate Aminotransferase Increase...	5 (.86%)
Drug Resistance	5 (.86%)
Gamma-glutamyltransferase Increased	5 (.86%)
Live Birth	5 (.86%)
Renal Failure Acute	5 (.86%)
Shock	5 (.86%)
Sinus Arrest	5 (.86%)
Agitation	4 (.69%)
Aplasia	4 (.69%)
Cholestasis	4 (.69%)
Hepatic Failure	4 (.69%)
Neutropenia	4 (.69%)
Pneumonia	4 (.69%)
Pneumonia Viral	4 (.69%)
Pneumothorax	4 (.69%)
Septic Shock	4 (.69%)
Torsade De Pointes	4 (.69%)
Anxiety	3 (.52%)
Arrhythmia	3 (.52%)
Aspergillosis	3 (.52%)
Cardiogenic Shock	3 (.52%)
Circulatory Collapse	3 (.52%)
Delirium	3 (.52%)
Extubation	3 (.52%)
General Physical Health Deteriorati...	3 (.52%)
Hepatic Enzyme Increased	3 (.52%)
Hepatic Function Abnormal	3 (.52%)
Hepatotoxicity	3 (.52%)
Hyperlactacidaemia	3 (.52%)
Leukopenia	3 (.52%)
Mechanical Ventilation	3 (.52%)
Pneumonia Staphylococcal	3 (.52%)
Pneumonitis	3 (.52%)
Pulmonary Embolism	3 (.52%)
Tachycardia	3 (.52%)
Tachypnoea	3 (.52%)
Ventricular Arrhythmia	3 (.52%)
Acidosis	2 (.34%)
Anuria	2 (.34%)
Ascites	2 (.34%)
Cardio-respiratory Arrest	2 (.34%)
Chills	2 (.34%)
Condition Aggravated	2 (.34%)
Convulsion	2 (.34%)
Cough	2 (.34%)
Drug Toxicity	2 (.34%)
Dyspnoea	2 (.34%)
Febrile Neutropenia	2 (.34%)
Gastrointestinal Haemorrhage	2 (.34%)
Haematotoxicity	2 (.34%)
Haemolysis	2 (.34%)
Haemorrhagic Stroke	2 (.34%)
Hepatomegaly	2 (.34%)
Hypocapnia	2 (.34%)
Hyporeflexia	2 (.34%)
Influenza	2 (.34%)
Intravascular Haemolysis	2 (.34%)
Ischaemia	2 (.34%)
Ischaemic Stroke	2 (.34%)
Lactic Acidosis	2 (.34%)
Linear Iga Disease	2 (.34%)
Malaise	2 (.34%)
Metabolic Alkalosis	2 (.34%)
Mutism	2 (.34%)
Nervous System Disorder	2 (.34%)
No Adverse Event	2 (.34%)
Overdose	2 (.34%)
Pregnancy	2 (.34%)
Pulmonary Fibrosis	2 (.34%)
Pulmonary Haemorrhage	2 (.34%)
Pupil Fixed	2 (.34%)
Respiratory Disorder	2 (.34%)
Retrograde Portal Vein Flow	2 (.34%)
Rhabdomyolysis	2 (.34%)
Transaminases Increased	2 (.34%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Zanamivir, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Zanamivir is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Zanamivir

What are the most common Zanamivir adverse events reported to the FDA?

Respiratory	45 (7.75%)
Cardiac Arrhythmias	42 (7.23%)
Hepatic And Hepatobiliary	42 (7.23%)
Renal Disorders	29 (4.99%)
Lower Respiratory Tract Disorders	28 (4.82%)
Fatal Outcomes	26 (4.48%)
Hepatobiliary	22 (3.79%)
Infections - Pathogen Unspecified	20 (3.44%)
Chemical Injury And Poisoning	18 (3.1%)
Decreased And Nonspecific Blood Pre...	15 (2.58%)
Anemias Nonhemolytic And Marrow Dep...	13 (2.24%)
	Show More
Therapeutic And Nontherapeutic Effe...	13 (2.24%)
Vascular	12 (2.07%)
Renal And Urinary Tract Investigati...	11 (1.89%)
Acid-base	10 (1.72%)
Hematology Investigations	10 (1.72%)
Platelet	10 (1.72%)
White Blood Cell	10 (1.72%)
Encephalopathies	9 (1.55%)
Anxiety Disorders	8 (1.38%)
Medication Errors	8 (1.38%)
Viral Infectious	8 (1.38%)
Abortions And Stillbirth	7 (1.2%)
Body Temperature Conditions	7 (1.2%)
Gastrointestinal Motility And Defec...	7 (1.2%)
Pregnancy, Labour, Delivery And Pos...	7 (1.2%)
Fungal Infectious	6 (1.03%)
Bacterial Infectious	5 (.86%)
Central Nervous System Vascular	5 (.86%)
Epidermal And Dermal Conditions	5 (.86%)
Neurological	5 (.86%)
Procedural And Device Related Injur...	5 (.86%)
Congenital And Hereditary	4 (.69%)
Heart Failures	4 (.69%)
Hemolyses And Related Conditions	4 (.69%)
Microbiology And Serology	4 (.69%)
Pleural	4 (.69%)
Deliria	3 (.52%)
Gastrointestinal Hemorrhages	3 (.52%)
Hematological	3 (.52%)
Pulmonary Vascular	3 (.52%)
Respiratory Tract Therapeutic Proce...	3 (.52%)
Seizures	3 (.52%)
Therapeutic Procedures And Supporti...	3 (.52%)
Arteriosclerosis, Stenosis, Vascula...	2 (.34%)
Communication Disorders	2 (.34%)
Disturbances In Thinking	2 (.34%)
Leukemias	2 (.34%)
Muscle	2 (.34%)
Ocular Neuromuscular	2 (.34%)
Peritoneal And Retroperitoneal Cond...	2 (.34%)
Upper Respiratory Tract Disorders	2 (.34%)
Bronchial Disorders	1 (.17%)
Cardiac And Vascular Investigations	1 (.17%)
Cardiac Disorder Signs	1 (.17%)
Changes In Physical Activity	1 (.17%)
Coagulopathies And Bleeding Diathes...	1 (.17%)
Coronary Artery	1 (.17%)
Enzyme	1 (.17%)
Exocrine Pancreas Conditions	1 (.17%)
Gallbladder	1 (.17%)
Gastrointestinal Inflammatory Condi...	1 (.17%)
Hematological And Lymphoid Tissue T...	1 (.17%)
Immune	1 (.17%)
Injuries	1 (.17%)
Maternal Complications Of Labour An...	1 (.17%)
Metabolic, Nutritional And Blood Ga...	1 (.17%)
Obstetric And Gynecological Therape...	1 (.17%)
Placental, Amniotic And Cavity Diso...	1 (.17%)
Psychiatric	1 (.17%)
Psychiatric And Behavioural Symptom...	1 (.17%)
Reproductive Tract	1 (.17%)
Skin And Subcutaneous Tissue	1 (.17%)
Sleep Disorders	1 (.17%)
Structural Brain	1 (.17%)
Toxicology And Therapeutic Drug Mon...	1 (.17%)
Vascular Hemorrhagic	1 (.17%)
Vision	1 (.17%)
Vulvovaginal Disorders	1 (.17%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Zanamivir, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Zanamivir is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.